Atreca (NASDAQ:BCEL) Trading 3.2% Higher

Posted by on Jun 6th, 2023

Shares of Atreca, Inc. (NASDAQ:BCEL – Get Rating) traded up 3.2% on Monday . The company traded as high as $1.05 and last traded at $1.03. 71,794 shares were traded during mid-day trading, a decline of 51% from the average session volume of 146,446 shares. The stock had previously closed at $1.00.

Wall Street Analyst Weigh In

BCEL has been the subject of several research analyst reports. Stifel Nicolaus reduced their target price on Atreca from $5.00 to $4.00 in a research note on Thursday, May 11th. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Atreca in a research note on Thursday, March 30th. Wedbush reiterated an “outperform” rating and set a $4.00 target price on shares of Atreca in a research note on Thursday, March 30th. Finally, EF Hutton Acquisition Co. I reiterated a “buy” rating and set a $10.00 target price on shares of Atreca in a research note on Thursday, March 30th.

Atreca Stock Performance

The firm has a market capitalization of $40.33 million, a price-to-earnings ratio of -0.43 and a beta of 1.08. The company has a fifty day moving average of $1.03 and a two-hundred day moving average of $1.20. The company has a debt-to-equity ratio of 0.97, a quick ratio of 4.24 and a current ratio of 4.24.

Atreca (NASDAQ:BCEL – Get Rating) last released its quarterly earnings results on Wednesday, March 29th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.01). As a group, equities research analysts predict that Atreca, Inc. will post -1.93 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Atreca

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd acquired a new position in Atreca in the 1st quarter valued at $41,000. IHT Wealth Management LLC acquired a new position in Atreca in the 1st quarter valued at $41,000. Advisor Group Holdings Inc. raised its holdings in Atreca by 111.8% in the 1st quarter. Advisor Group Holdings Inc. now owns 16,573 shares of the company’s stock valued at $52,000 after acquiring an additional 8,750 shares in the last quarter. Charles Schwab Investment Management Inc. acquired a new position in Atreca in the 1st quarter valued at $26,000. Finally, Virtu Financial LLC raised its holdings in Atreca by 248.8% in the 1st quarter. Virtu Financial LLC now owns 45,574 shares of the company’s stock valued at $144,000 after acquiring an additional 32,508 shares in the last quarter. 40.20% of the stock is owned by institutional investors and hedge funds.

Atreca Company Profile

(Get Rating)

Atreca, Inc operates as a clinical-stage biopharmaceutical company, which engages in developing novel antibody-based therapeutics to treat a range of solid tumor types. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response.

Featured Stories

Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.